Pharmaceutical In final guidance published yesterday, the UK's National Institute for Health and Clinical Excellence (NICE) has recommended Abilify (aripiprazole), from US drug major Bristol-Myers Squibb (NYSE: BMY and Japan's Otsuka Pharmaceuticals (4768: JP) as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone. 27 January 2011